{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:16:20Z","timestamp":1791260180512,"version":"4.1.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Many factors have been described to contribute to voriconazole (VCZ) interpatient variability in plasma concentrations, especially CYP2C19 genetic variability. In 2014, Hicks et al. presented data describing the correlation between VCZ plasma concentrations and CYP2C19 diplotypes in immunocompromised pediatric patients and utilized pharmacokinetic modeling to extrapolate a more suitable VCZ dose for each CYP2C19 diplotype. In 2017, in our hospital, a clinical protocol was developed for individualization of VCZ in immunocompromised patients based on preemptive genotyping of CYP2C19 and dosing proposed by Hicks et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) clinical guidelines, and routine therapeutic drug monitoring (TDM). We made a retrospective review of a cohort of 28 immunocompromised pediatric patients receiving VCZ according to our protocol. CYP2C19 gene molecular analysis was preemptively performed using PharmArray<jats:sup>\u00ae<\/jats:sup>. Plasma trough concentrations were measured by immunoassay analysis until target concentrations (1\u20135.5\u00a0\u03bcg\/ml) were reached. Sixteen patients (57.14%) achieved VCZ trough target concentrations in the first measure after the initial dose based on PGx. This figure is similar to estimations made by Hicks et al. in their simulation (60%). Subdividing by phenotype, our genotyping and TDM-combined strategy allow us to achieve target concentrations during treatment\/prophylaxis in 90% of the CYP2C19 Normal Metabolizers (NM)\/Intermediate Metabolizers (IM) and 100% of the Rapid Metabolizers (RM) and Ultrarapid Metabolizers (UM) of our cohort. We recommended modifications of the initial dose in 29% (<jats:italic>n<\/jats:italic> = 8) of the patients. In RM \u226512 years old, an increase of the initial dose resulted in 50% of these patients achieving target concentrations in the first measure after initial dose adjustment based only on PGx information. Our experience highlights the need to improve VCZ dose predictions in children and the potential of preemptive genotyping and TDM to this aim. We are conducting a multicenter, randomized clinical trial in patients with risk of aspergillosis in order to evaluate the effectiveness and efficiency of VCZ individualization: VORIGENIPHARM (EudraCT: 2019-000376-41).<\/jats:p>","DOI":"10.3389\/fphar.2021.717932","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T22:38:07Z","timestamp":1634769487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Irene","family":"Garc\u00eda-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dap\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Montserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Martinez de Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Queiruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Rodriguez Mariblanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Guerra-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio J.","family":"Carcas-Sansuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Borobia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","article-title":"Therapeutic Drug Monitoring (TDM) of Antifungal Agents: Guidelines from the British Society for Medical Mycology","volume":"69","author":"Ashbee","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/jac\/dkw056","article-title":"Voriconazole Dosing and Therapeutic Drug Monitoring in Children: Experience from a Paediatric Tertiary Care centre","volume":"71","author":"Boast","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","article-title":"The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database","volume":"103","author":"Gaedigk","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/FPC.0000000000000277","article-title":"Impact of the CYP2C19 Genotype on Voriconazole Exposure in Adults with Invasive Fungal Infections","volume":"27","author":"Hamadeh","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2217\/pgs.14.53","article-title":"Voriconazole Plasma Concentrations in Immunocompromised Pediatric Patients Vary by CYP2C19 Diplotypes","volume":"15","author":"Hicks","year":"2014","journal-title":"Pharmacogenomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.1641","article-title":"Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients with Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations","volume":"107","author":"Hicks","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/00912700103955108","article-title":"Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole after Single and Multiple Doses in Healthy Volunteers","volume":"52","author":"Lee","year":"2012","journal-title":"J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of Voriconazole Therapeutic Drug Monitoring: a Meta-Analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of Voriconazole Therapeutic Drug Monitoring: a Meta-Analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1469-0691.2009.02990.x","article-title":"Voriconazole Concentrations and Outcome of Invasive Fungal Infections","volume":"16","author":"Miyakis","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e037443","DOI":"10.1136\/bmjopen-2020-037443","article-title":"Randomised Multicentre Clinical Trial to Evaluate Voriconazole Pre-emptive Genotyping Strategy in Patients with Risk of Aspergillosis: Vorigenipharm Study Protocol","volume":"10","author":"Monserrat Villatoro","year":"2020","journal-title":"BMJ Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B13","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy","author":"Moriyama","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?","volume":"34","author":"Owusu Obeng","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: a Randomized Controlled Trial","volume":"55","author":"Park","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/cpt.1642","article-title":"Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis after Allogeneic Hematopoietic Cell Transplant","volume":"107","author":"Patel","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1365-2125.2009.03534.x","article-title":"Pharmacokinetics, Metabolism and Bioavailability of the Triazole Antifungal Agent Voriconazole in Relation to CYP2C19 Genotype","volume":"68","author":"Scholz","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/myc.12552","article-title":"Economic Evaluation of Azoles as Primary Prophylaxis for the Prevention of Invasive Fungal Infections in Spanish Patients Undergoing Allogeneic Haematopoietic Stem Cell Transplant","volume":"60","author":"Solano","year":"2017","journal-title":"Mycoses"},{"key":"B20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from Bench to Byte-Aan Update of Guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jac\/dkt369","article-title":"Identification of Factors Influencing the Pharmacokinetics of Voriconazole and the Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients with Invasive Fungal Infections","volume":"69","author":"Wang","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ijantimicag.2014.07.013","article-title":"Efficacy and Safety of Voriconazole and CYP2C19 Polymorphism for Optimised Dosage Regimens in Patients with Invasive Fungal Infections","volume":"44","author":"Wang","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics Knowledge for Personalized Medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.717932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T22:38:10Z","timestamp":1634769490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.717932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":23,"alternative-id":["10.3389\/fphar.2021.717932"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.717932","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"article-number":"717932"}}